Nicole believes that the strategic vision of developing robust relationships, proactively, is the key to creating and delivering results that are both sustainable and tangible. Through this collaborative approach, she openly involves people in the mission of the business/project and from this, outstanding results are created. Her commercial expertise has been built from a drug discovery research base with substantial experience in product development, raising capital, IP strategy, securing grant funding and licensing new technologies. Nicole Signal has over 20 years experience working in drug development, in CEO, Operations and Development roles within a number of venture capital backed start-up biotechnology and drug development companies in New Zealand (Proacta, Pathway Therapeutics, Saratan Therapeutics), Australia (Neuprotect, Nephrodynamics, Cortical, Paranta), the UK (Almac) and USA (Glaxo SmithKline, Parexel). Nicole has a BSc (Hons) in Biochemistry from Monash University and an MBA from Melbourne Business School. Nicole Signal presently works at Evermore Clinical Trials, the trust that oversees all commercial and grant funded research at Counties Manukau District Health Board, in Auckland. In the remainder of her time, Nicole is also leading the set-up of a large sterile injectable facility in the Philippines.

Biochemistry , BIOTECHNOLOGY